Company news
Plus Therapeutics, Inc. (NASDAQ:PSTV) news
Plus Therapeutics, Inc. news releases on 6ix. Latest, Aug 14, 2025: Plus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO…
Press releases — page 2
Plus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO CNS Metastases Conference
August 14, 2025
Plus Therapeutics Provides US Launch Update for its CNSide® Diagnostic
July 31, 2025
Plus Therapeutics Announces $1.6 Million Advance Payment from CPRIT
July 23, 2025
Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases
July 15, 2025
Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference
July 10, 2025
Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases
July 8, 2025
Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases
June 30, 2025
Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary
June 26, 2025
Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, June 26, 2025 at 9:00 A.M. ET
June 25, 2025
Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain Cancer
June 25, 2025
Plus Therapeutics Announces Comprehensive Restructuring of $15 Million March 2025 Equity Financing
June 24, 2025
Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights
May 30, 2025
Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q
May 23, 2025
Plus Therapeutics’ REYOBIQ™ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM)
May 14, 2025
Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference
May 8, 2025
Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors
April 23, 2025
Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases
April 15, 2025
Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
March 27, 2025
Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate
March 20, 2025
Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025
March 19, 2025
Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders’ Equity Requirement
March 10, 2025
Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma
March 7, 2025
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer
March 6, 2025
Plus Therapeutics Announces New Employment Inducement Grants
March 5, 2025
Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds
March 4, 2025
Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with Leptomeningeal Metastases
February 26, 2025
Plus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics Subsidiary
February 24, 2025
Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer
February 20, 2025
Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program
February 18, 2025
Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope Supply
December 2, 2024
Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal Metastases
November 21, 2024
Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases
November 20, 2024
Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership
November 5, 2024
Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting
September 30, 2024
Plus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 13, 2024
Plus Therapeutics Presents Positive Clinical Trial Results at the 2024 SNO/ASCO CNS Metastases Conference
August 12, 2024
Plus Therapeutics Presents Positive Interim ReSPECT-LM Phase 1 Data for Leptomeningeal Metastases at 2024 SNO/ASCO CNS Metastases Conference
August 11, 2024
Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT
June 6, 2024
Plus Therapeutics Announces Private Placement Financing of up to $18 Million
May 5, 2024
Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense
April 21, 2024
Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic
March 24, 2024
Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases
March 10, 2024
Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
March 4, 2024
Plus Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on March 5, 2024
February 26, 2024
Plus Updates Financial and Cash Guidance for 2024
December 17, 2023
Plus Therapeutics Partners With K2bio for Development of Novel Tests for Cerebrospinal Fluid (CSF) Tumor Cell and Molecular Biomarker Analyses
December 11, 2023
Plus Therapeutics Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar
November 19, 2023
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to Rhenium (186Re) Obisbemeda for the Treatment of Breast Cancer with Leptomeningeal Metastases
November 2, 2023
Plus Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
October 30, 2023
Plus Therapeutics Announces Share Repurchase Program
October 30, 2023